Discovery of γ-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor α converting enzyme: Design, synthesis, and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 4954-4957

  Duan, James J W ^a   Chen, Lihua ^a   Wasserman, Zelda R ^a   Lu, Zhonghui ^a   Liu, Rui Qin ^a   Covington, Maryanne B ^a   Qian, Mingxin ^a   Hardman, Karl D ^a   Magolda, Ronald L ^a   Newton, Robert C ^a   Christ, David D ^a   Wexler, Ruth R ^a   Decicco, Carl P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA LACTAM DERIVATIVE; HYDROXAMIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; BIOAVAILABILITY; COMPUTER MODEL; ENZYME SYNTHESIS; MEMBRANE BINDING; RECEPTOR BINDING; RHEUMATIC DISEASE; STRUCTURE ACTIVITY RELATION;

ADAM PROTEINS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; HYDROXAMIC ACIDS; LACTAMS; MATRIX METALLOPROTEINASE 3; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 0037038311     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0255670     Document Type: Article

References (25)

1. (a) Aggarwal, B. B.; Kohr, W. J.; Hass, P. E.; Moffat, B.; Spencer, S. A.; Henzel, W. J.; Bringman, T. S.; Nedwin, G. E.; Goeddel, D. V.; Harkins, R. N. Human tumour necrosis factor: Production, purification and characterization. J. Biol. Chem. 1985, 260, 2345-2354.
2. (b) Newton, R. C.; Decicco, C. P. Therapeutical. Potential and strategies for inhibiting tumor necrosis factor- α. J. Med. Chem. 1999, 42, 2295-2314.
3. (a) Moreland, L. W.; Baumgartner, S. W.; Schiff, M. H.; Tindall, E. A.; Fleischmann, R. M.; Weaver, A. L.; Ettlinger, R. E.; Cohen, S.; Koopman, W. J.; Mohler, K.; Widmer, M. B.; Blosch, C. M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997, 337, 141-147.
4. (b) Lipsky, P. E.; van der Heijde, D. M. F. M. E.; St. Clair, W.; Furst, D. E.; Breedveld, F. C.; Kalden, J. R.; Smolen, J. S.; Weisman, M.; Emery, P.; Feldmann, M.; Harriman, G. R.; Maini, R. N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000, 343, 1594-1602.
5. (a) Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.; Wolfson, M. F.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Bolani, N.; Schooley, K. A.; Gerhart, M.; Devis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P. A metalloproteinase disintegrin that releases tumour necrosis factor-α from cells. Nature 1997, 385, 729-733.
6. (b) Moss, M. L.; Jin, S.-L. C.; Milla, M. E.; Burkhart, W.; Carter, H. L.; Chen, W.-J.; Clay, W. C.; Didsbury, J. R.; Hassler, D.; Hoffman, C. R.; Kost, T. A.; Lambert, M. H.; Leesnitzer, M. A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L. K.; Schoenen, F.; Seaton, T.; Su, J.-L.; Warner, J.; Willard, D.; Becherer, J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997, 385, 733-736.
7. (a) Xue, C.-B.; Voss, M. E.; Nelson, D. J.; Duan, J. J.-W.; Cherney, R. J.; Jacobson, I. C.; He, X.; Roderick, J.; Chen, L.; Corbett, R. L.; Wang, L.; Meyer, D. T.; Kennedy, K.; DeGrado, W. F.; Hardman, K. D.; Teleha, C. A.; Jaffee, B. D.; Liu, R.-Q.; Copeland, R. A.; Covington, M. B.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Magolda, R. L.; Wexler, R. R.; Decicco, C. P. Design, synthesis, and structure -activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor-α release in vitro and in vivo. J. Med. Chem. 2001, 44, 2636-2660.
8. (b) Xue, C.-B.; He, X.; Corbett, R. L.; Roderick, J.; Wasserman, Z. R.; Liu, R.-Q.; Jaffee, B. D.; Covington, M. B.; Qian, M.; Trzaskos, J. M.; Newton, R. C.; Magolda, R. L.; Wexler, R. R.; Decicco, C. P. Discovery of Macrocyclic Hydroxamic Acids Containing Biphenylmethyl Derivatives at P1′, a Series of Selective TNF-α Converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-α release. J. Med. Chem. 2001, 44, 3351-3354.
9. (a) Rabinowitz, M. H.; Andrews, R. C.; Becherer, J. D.; Bickett, D. M.; Bubacz, D. G.; Conway, J. G.; Cowan, D. J.; Gaul, M.; Glennon, K.; Lambert, M. H.; Leesnitzer, M. A.; McDougald, D. L.; Moss, M. L.; Musso, D. L.; Rizzolio, M. C. Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE). J. Med. Chem. 2001, 44, 4252-4267.
10. (b) Holms, J.; Mast, K.; Marcotte, P.; Elmore, I.; Li, J.; Pease, L.; Glaser, K.; Morgan, D.; Michaelides, M.; Davidsen, S. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme. Bioorg. Med. Chem. Lett. 2001, 11, 2907-2910.
11. (c) Chen, J. M.; Jin, G.; Sung, A.; Levin, J. I. Anthranilate sulfonamide hydroxamate tace inhibitors. Part 1: Structure-based design of novel acetylenic p1′ groups. Bioorg. Med. Chem. Lett. 2002, 12, 1195-1198.
12. (d) Levin, J. I.; Chen, J. M.; Du, M. T.; Nelson, F. C.; Killar, L. M.; Skala, S.; Sung, A.; Jin, G.; Cowling, R.; Barone, D.; March, C. J.; Mohler, K. M.; Black, R. A.; Skotnicki, J. S. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group. Bioorg. Med. Chem. Lett. 2002, 12, 1199-1202.
13. (e) Letavic, M. A.; Axt, M. Z.; Barberia, J. T.; Carty, T. J.; Danley, D. E.; Geoghegan, K. F.; Halim, N. S.; Hoth, L. R.; Kamath, A. V.; Laird, E. R.; Lopresti-Morrow, L. L.; McClure, K. F.; Mitchell, P. G.; Natarajan, V.; Noe, M. C.; Pandit, J.; Reeves, L.; Schulte, G. K.; Snow, S. L.; Sweeney, F. J.; Tan, D. H.; Yu, C. H. Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1387-1390.
14. During the course of this work, a patent application disclosing unrelated lactam-based MMP inhibitors was published: Jacobsen, E. J. PCT Int. Appl. WO 9732846. After completion of this work, another series of unrelated lactam-based MMP inhibitors was published: Robinson, R. P.; Laird, E. R.; Blake, J. F.; Bordner, J.; Donahue, K. M.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Reese, M. R.; Reeves, L. M.; Stam, E. J.; Yocum, S. A. Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitors based on pyrrolidinone scaffold. J. Med. Chem. 2000, 43, 2293-2296.
15. During the course of this work, a patent application disclosing unrelated lactam-based MMP inhibitors was published: Jacobsen, E. J. PCT Int. Appl. WO 9732846. After completion of this work, another series of unrelated lactam-based MMP inhibitors was published: Robinson, R. P.; Laird, E. R.; Blake, J. F.; Bordner, J.; Donahue, K. M.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Reese, M. R.; Reeves, L. M.; Stam, E. J.; Yocum, S. A. Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitors based on pyrrolidinone scaffold. J. Med. Chem. 2000, 43, 2293-2296.
16. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today 1996, 1, 16-26.
17. (a) MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532.
18. (b) Li, Y.-C.; Zhang, X.; Melton, R.; Ganu, V.; Gonnella, N. C. Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry 1998, 37, 14048-14056.
19. (c) Nar, H.; Werle, K.; Bauer, M. M. T.; Dollinger, H.; Jung, B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J. Mol. Biol. 2001, 312, 743-751.
20. Wojtowicz-Praga, S.; Torri, J.; Johnson, M.; Steen, V.; Marshall, J.; Ness, E.; Dickson, R.; Sale, M.; Rasmussen, H. S.; Chiodo, T. A.; Hawkins, M. J. Phase I trail of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 1998, 16, 2150-2156.
21. Selectivity profile was assessed using MMP-1 as a representative with a shallow S1′ pocket and using MMP-2 and -9 with deep S1′ pockets. Details of the assays are described in ref 4a.
22. Details of pTACE and WBA are described in ref 4a.
23. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal structure of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 1999, 6, 217-221.
24. Schlondorff, J.; Becherer, J. D.; Blobel, C. P. Intracellular maturation and localization of the tumour necrosis factor α convertase (TACE). Biochem. J. 2000, 347, 131-138.
25. Wu, J.-T.; Zeng, H.; Qian, M.; Brogdon, B. L.; Unger, S. E. Direct plasma sample injection in multiple -component LC-MS-MS assays for high-throughput pharmacokinetic screening. Anal. Chem. 2000, 72, 61-67.